Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

OCUL | Ocular Therapeutix Inc

Index	RUT	P/E	-	EPS (ttm)	-1.17	Insider Own	5.33%	Shs Outstand	77.20M	Perf Week	-3.92%
Market Cap	253.25M	Forward P/E	-	EPS next Y	-0.91	Insider Trans	0.13%	Shs Float	75.16M	Perf Month	-15.16%
Income	-90.73M	PEG	-	EPS next Q	-0.29	Inst Own	54.72%	Short Float / Ratio	5.47% / 5.11	Perf Quarter	-32.98%
Sales	54.60M	P/S	4.64	EPS this Y	-25.82%	Inst Trans	-2.89%	Short Interest	4.11M	Perf Half Y	-35.16%
Book/sh	0.04	P/B	81.88	EPS next Y	21.75%	ROA	-61.38%	Target Price	12.62	Perf Year	-44.23%
Cash/sh	0.84	P/C	3.80	EPS next 5Y	50.08%	ROE	-263.41%	52W Range	2.57 - 7.96	Perf YTD	13.52%
Dividend	-	P/FCF	-	EPS past 5Y	15.93%	ROI	-141.63%	52W High	-59.92%	Beta	1.25
Dividend %	-	Quick Ratio	3.04	Sales past 5Y	119.20%	Gross Margin	91.57%	52W Low	24.12%	ATR	0.18
Employees	274	Current Ratio	3.11	Sales Q/Q	23.81%	Oper. Margin	-153.89%	RSI (14)	27.84	Volatility	4.01% 4.62%
Optionable	Yes	Debt/Eq	20.96	EPS Q/Q	-7.20%	Profit Margin	-166.17%	Rel Volume	0.52	Prev Close	3.19
Shortable	Yes	LT Debt/Eq	19.73	Earnings	Aug 07 AMC	Payout	-	Avg Volume	804.80K	Price	3.19
Recom	1.38	SMA20	-12.91%	SMA50	-21.40%	SMA200	-33.16%	Volume	419,702	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-21-23	Initiated	Robert W. Baird	Outperform	$18
Aug-10-22	Resumed	Berenberg	Buy	$15
Aug-10-21	Upgrade	H.C. Wainwright	Neutral → Buy	$17
Dec-28-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-17-20	Initiated	Berenberg	Buy	$27
Nov-13-20	Reiterated	Raymond James	Strong Buy	$15 → $25
Aug-10-20	Reiterated	H.C. Wainwright	Buy	$10 → $13
Mar-03-20	Upgrade	Raymond James	Outperform → Strong Buy
May-21-19	Reiterated	H.C. Wainwright	Buy	$12 → $9
May-21-19	Downgrade	Raymond James	Strong Buy → Outperform	$11 → $5
May-21-19	Downgrade	Cowen	Outperform → Market Perform	$13 → $3
Dec-03-18	Reiterated	Cantor Fitzgerald	Overweight	$22 → $24
Nov-15-18	Initiated	Raymond James	Strong Buy	$10
Sep-07-18	Initiated	Piper Jaffray	Overweight
Oct-24-17	Initiated	Guggenheim	Buy	$12
Jul-26-17	Initiated	H.C. Wainwright	Buy	$10
Jul-12-17	Reiterated	Cantor Fitzgerald	Overweight	$35 → $21
Jun-23-17	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-10-17	Initiated	Cantor Fitzgerald	Overweight	$35
Nov-15-16	Reiterated	RBC Capital Mkts	Outperform	$30 → $32

Show Previous Ratings

Sep-19-23 09:00PM	AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery (PR Newswire)
Sep-06-23 08:00AM	Ocular Therapeutix to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Aug-09-23 08:00AM	Ocular Therapeutix to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-08-23 11:13AM	Q2 2023 Ocular Therapeutix Inc Earnings Call (Thomson Reuters StreetEvents) -10.78%
Aug-07-23 07:15PM	Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:05PM	Loading…
06:05PM	Ocular Therapeutix: Q2 Earnings Snapshot (AP Finance)
04:01PM	Ocular Therapeutix Provides Second Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Jul-24-23 08:00AM	Ocular Therapeutix To Report Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-14-23 06:59AM	Strength Seen in Avita Medical Inc. (RCEL): Can Its 20.4% Jump Turn into More Strength? (Zacks)
Jul-13-23 09:00AM	10 Best Rising Penny Stocks to Buy (Insider Monkey)
Jul-12-23 08:00AM	Ocular Therapeutix Announces Appointment of New Board Member (GlobeNewswire)
Jun-10-23 06:30PM	Ocular Therapeutix Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD (GlobeNewswire)
Jun-07-23 08:00AM	Ocular Therapeutix Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy (GlobeNewswire)
Jun-05-23 04:01PM	Ocular Therapeutix To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting (GlobeNewswire)
Jun-02-23 09:37AM	Ocular Therapeutix, Inc. (NASDAQ:OCUL) is definitely on the radar of institutional investors who own 45% of the company (Simply Wall St.) +7.79%
08:00AM	Loading…
Jun-01-23 08:00AM	Ocular Therapeutix to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-23 11:42AM	3 Low-Priced Stocks -- And How I'm Trading Them (TheStreet.com)
06:21AM	Q1 2023 Ocular Therapeutix Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 06:15PM	Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
05:07PM	Ocular Therapeutix: Q1 Earnings Snapshot (AP Finance)
04:01PM	Ocular Therapeutix Provides First Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
08:00AM	Ocular Therapeutix to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
May-04-23 09:50AM	Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Intrinsic Value Is Potentially 32% Above Its Share Price (Simply Wall St.)
Apr-28-23 08:00AM	Ocular Therapeutix To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (GlobeNewswire)
Apr-24-23 08:00AM	Ocular Therapeutix To Report First Quarter 2023 Financial Results (GlobeNewswire)
Apr-14-23 04:01PM	Ocular Therapeutix To Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire)
Apr-07-23 08:49AM	Ocular Therapeutix (NASDAQ:OCUL) shareholders have endured a 21% loss from investing in the stock five years ago (Simply Wall St.)
Mar-11-23 07:22AM	Downgrade: Here's How Analysts See Ocular Therapeutix, Inc. (NASDAQ:OCUL) Performing In The Near Term (Simply Wall St.)
Mar-08-23 08:50AM	What Makes Ocular Therapeutix (OCUL) a Good Fit for 'Trend Investing' (Zacks)
07:21AM	Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2022 Earnings Call Transcript (Insider Monkey)
05:37AM	Loading…
05:37AM	Ocular Therapeutix Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Mar-07-23 08:40AM	Q4 2022 Ocular Therapeutix Inc Earnings Call (Thomson Reuters StreetEvents) +5.29%
Mar-06-23 05:15PM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.58%
04:01PM	Ocular Therapeutix Provides Fourth Quarter and Year-End 2022 Results and Corporate Update (GlobeNewswire)
Feb-28-23 08:00AM	Ocular Therapeutix to Present at Cowens 43rd Annual Healthcare Conference (GlobeNewswire)
Feb-27-23 05:15PM	Chinook Therapeutics (KDNY) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-21-23 08:00AM	Ocular Therapeutix To Report Fourth Quarter and Year-End 2022 Financial Results (GlobeNewswire) -8.45%
Feb-16-23 05:15PM	Why Shares of Ocular Therapeutix Jumped This Week (Motley Fool)
Feb-13-23 05:52AM	Ocular Therapeutix Shares Jump On Favorable Data From Intravitreal Implant Study In Wet AMD (Benzinga) +35.14%
Feb-11-23 08:00AM	Ocular Therapeutix Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD (GlobeNewswire)
Jan-06-23 08:00AM	Ocular Therapeutix Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones (GlobeNewswire) +16.40%
Dec-24-22 07:34AM	With 48% stake, Ocular Therapeutix, Inc. (NASDAQ:OCUL) seems to have captured institutional investors' interest (Simply Wall St.)
Nov-13-22 07:10AM	These Analysts Just Made A Neat Downgrade To Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Forecasts (Simply Wall St.)
Nov-08-22 08:00AM	Ocular Therapeutix to Participate at Three Upcoming Investor Conferences (Business Wire) -10.99%
05:38AM	Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised) (Zacks)
Nov-07-22 05:25PM	Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
05:25PM	Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised) (Zacks)
04:01PM	Ocular Therapeutix Reports Third Quarter 2022 Financial Results and Business Update (Business Wire)
Oct-24-22 06:00AM	Ocular Therapeutix To Report Third Quarter 2022 Financial Results (Business Wire)
Oct-17-22 08:11AM	Investors in Ocular Therapeutix (NASDAQ:OCUL) have unfortunately lost 63% over the last year (Simply Wall St.)
Sep-30-22 09:27AM	Ocular Therapeutix (OCUL) Soars 24.2%: Is Further Upside Left in the Stock? (Zacks) -19.10%
Sep-27-22 10:21AM	Ocular Therapeutix's Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea (Benzinga) -18.37%
06:00AM	Ocular Therapeutix Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD (Business Wire)
Sep-22-22 07:00AM	Ocular Therapeutix To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting (Business Wire)
Sep-07-22 04:01PM	Ocular Therapeutix to Present at the H.C. Wainwright 24th Annual Global Investment Conference (Business Wire) +8.69%
Aug-10-22 08:00AM	Ocular Therapeutix to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference (Business Wire) +18.33%
Aug-08-22 05:45PM	Ocular Therapeutix (OCUL) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Ocular Therapeutix Reports Second Quarter 2022 Financial Results and Business Update (Business Wire)
Jul-25-22 08:00AM	Ocular Therapeutix To Report Second Quarter 2022 Financial Results (Business Wire)
Jul-13-22 01:58PM	Could The Ocular Therapeutix, Inc. (NASDAQ:OCUL) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Jun-13-22 01:23PM	Is Ocular Therapeutix (NASDAQ:OCUL) A Risky Investment? (Simply Wall St.)
Jun-08-22 07:00AM	Ocular Therapeutix Announces Organizational Changes to Support Development for Retinal Diseases (Business Wire)
Jun-01-22 08:00AM	Ocular Therapeutix to Present at the Jefferies Healthcare Conference (Business Wire)
May-13-22 06:03AM	Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Just Slashed This Year's Revenue Estimates By 20% (Simply Wall St.) +8.97%
May-09-22 05:45PM	Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -6.05%
04:01PM	Ocular Therapeutix Reports First Quarter 2022 Financial Results and Business Update (Business Wire)
May-03-22 05:35PM	Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Ocular Therapeutix To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting (Business Wire)
Apr-26-22 08:00AM	Ocular Therapeutix to Report First Quarter 2022 Financial Results (Business Wire)
Apr-25-22 08:00AM	Ocular Therapeutix to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (Business Wire) +6.83%
Apr-14-22 04:35PM	Ocular Therapeutix to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (Business Wire)
Apr-12-22 10:46PM	AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery (PR Newswire)
Mar-04-22 08:00AM	Ocular Therapeutix to Present at the Cowen 42nd Annual Healthcare Conference (Business Wire)
Mar-02-22 07:28AM	Time To Worry? Analysts Are Downgrading Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Outlook (Simply Wall St.)
Feb-28-22 05:35PM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Ocular Therapeutix Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update (Business Wire)
Feb-23-22 06:05PM	Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Feb-22-22 08:00AM	Ocular Therapeutix To Report Fourth Quarter and Year-End 2021 Financial Results (Business Wire)
Feb-11-22 08:00AM	Ocular Therapeutix Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360 (Business Wire)
Jan-18-22 08:00AM	AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients (Business Wire) -6.45%
Jan-12-22 09:38AM	Hikari Power Ltd Buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Sells ... (GuruFocus.com)
Jan-04-22 08:00AM	Ocular Therapeutix to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference (Business Wire)
07:44AM	Ocular Therapeutix (NASDAQ:OCUL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway (Simply Wall St.)
Dec-06-21 07:00AM	Ocular Therapeutix Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease (Business Wire)
Nov-20-21 06:09AM	3 Small-Cap Stocks to Buy Now and Hold for the Long Haul (Motley Fool)
Nov-15-21 08:00AM	Ocular Therapeutix to Participate at Two Upcoming Investor Conferences (Business Wire)
Nov-09-21 01:17PM	Ocular Therapeutix Stock Gains As Court Invalidates Drug Delivery Patent From Mati (Benzinga) +7.46%
09:06AM	Ocular Therapeutix Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc. (Business Wire)
Nov-08-21 07:35PM	Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Ocular Therapeutix Reports Third Quarter 2021 Financial Results and Business Update (Business Wire)
Nov-05-21 11:44AM	Could The Ocular Therapeutix, Inc. (NASDAQ:OCUL) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
09:00AM	Ocular Therapeutix Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA® (Business Wire)
Nov-01-21 08:00AM	Ocular Therapeutix to Present Data at the American Academy of Optometry Annual Meeting 2021 (Business Wire) +6.63%
Oct-29-21 04:01PM	Ocular Therapeutix To Report Third Quarter 2021 Financial Results (Business Wire)
Oct-28-21 03:05PM	Earnings Preview: Ocular Therapeutix (OCUL) Q3 Earnings Expected to Decline (Zacks)
08:00AM	Ocular Therapeutix to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting (Business Wire)
Oct-25-21 03:13PM	Hedge Funds Are Crazy About Ocular Therapeutix Inc (OCUL) (Insider Monkey) +6.80%
Oct-24-21 10:00AM	Are Atea Pharmaceuticals, Agenus, Novavax, and Ocular Therapeutix Bad News Buy? (Motley Fool)
Oct-22-21 03:30PM	Mid-Afternoon Market Update: Nasdaq Down 70 Points; Ocular Therapeutix Shares Drop (Benzinga) -36.20%
11:25AM	Here's Why Ocular Therapeutix Stock Is Sinking Today (Motley Fool)

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mattessich Antony C.	President and CEO	Aug 30	Buy	3.81	6,500	24,765	6,500	Sep 05 08:27 AM
Ozden Rabia Gurses	Chief Medical Officer	Jul 07	Sale	4.93	832	4,102	100,531	Jul 11 08:00 PM
Mattessich Antony C.	President and CEO	Feb 06	Sale	4.24	19,669	83,397	446,281	Feb 08 07:29 PM
Notman Donald	Chief Financial Officer	Feb 06	Sale	4.24	6,476	27,458	139,387	Feb 08 07:32 PM
Ozden Rabia Gurses	Chief Medical Officer	Feb 06	Sale	4.24	6,416	27,204	101,363	Feb 08 07:33 PM
Strassburger Philip C.	General Counsel	Feb 06	Sale	4.24	6,181	26,207	109,071	Feb 08 07:31 PM
White Christopher G	Chief Business Officer	Feb 06	Sale	4.24	5,829	24,715	94,766	Feb 08 07:38 PM
SUMMER ROAD LLC	10% Owner	Nov 07	Buy	3.50	7,328	25,648	6,122,089	Nov 09 04:48 PM
SUMMER ROAD LLC	10% Owner	Oct 11	Buy	3.90	10,000	38,993	6,114,761	Oct 12 04:34 PM
SUMMER ROAD LLC	10% Owner	Oct 10	Buy	4.00	10,000	39,982	6,104,761	Oct 12 04:34 PM
SUMMER ROAD LLC	10% Owner	Sep 29	Buy	4.04	18,800	75,988	6,094,761	Sep 29 07:51 PM
SUMMER ROAD LLC	10% Owner	Sep 28	Buy	4.10	1,200	4,920	6,075,961	Sep 29 07:51 PM
SUMMER ROAD LLC	10% Owner	Sep 27	Buy	4.68	130,000	608,322	6,074,761	Sep 29 07:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCUL | Ocular Therapeutix Inc

Upgrade your FINVIZ experience